FDA main­tains Covid flex­i­bil­i­ties for IRB re­view of ex­pand­ed ac­cess drugs for in­di­vid­u­als

The FDA in­di­cat­ed that it will main­tain some pan­dem­ic-era flex­i­bil­i­ties in in­sti­tu­tion­al re­view board (IRB) as­sess­ments of ex­pand­ed ac­cess drugs for in­di­vid­ual pa­tients in im­me­di­ate­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER